Related Experiment Video
Updated: May 18, 2026
High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication
Published on: October 30, 2021
A limited structural modification results in a significantly more efficacious diazachrysene-based filovirus inhibitor
Zivota Selaković1, Dejan Opsenica, Brett Eaton
1University of Belgrade, Studentski trg 16, P.O. Box 51, Belgrade 11158, Serbia. zivota.selakovic@gmail.com
Abstract:
Ebola (EBOV) and Marburg (MARV) filoviruses are highly infectious pathogens causing deadly hemorrhagic fever in humans and non-human primates. Promising vaccine candidates providing immunity against filoviruses have been reported. However, the sporadic nature and swift progression of filovirus disease underlines the need for the development of small molecule therapeutics providing immediate antiviral effects. Herein we describe a brief structural exploration of two previously reported diazachrysene (DAAC)-based EBOV inhibitors. Specifically, three analogs were prepared to examine how slight substituent modifications would affect inhibitory efficacy and inhibitor-mediated toxicity during not only EBOV, but also MARV cellular infection. Of the three analogs, one was highly efficacious, providing IC(50) values of 0.696 µM ± 0.13 µM and 2.76 µM ± 0.21 µM against EBOV and MARV infection, respectively, with little or no associated cellular toxicity. Overall, the structure-activity and structure-toxicity results from this study provide a framework for the future development of DAAC-based filovirus inhibitors that will be both active and non-toxic in vivo.
Insights
Researchers explored diazachrysene (DAAC) compounds as potential treatments for Ebola (EBOV) and Marburg (MARV) virus infections. One novel DAAC analog demonstrated high efficacy against both filoviruses with minimal toxicity, offering a promising therapeutic avenue.
Area of Science:
- Virology
- Medicinal Chemistry
- Drug Discovery
Background:
- Ebola (EBOV) and Marburg (MARV) viruses are highly infectious filoviruses causing severe hemorrhagic fever.
- Existing vaccine candidates show promise, but rapid-onset filovirus diseases necessitate immediate-acting small molecule therapeutics.
- Diazachrysene (DAAC)-based compounds have previously shown potential as EBOV inhibitors.
Purpose of the Study:
- To explore the structure-activity and structure-toxicity relationships of novel diazachrysene (DAAC)-based compounds.
- To evaluate the efficacy of modified DAAC analogs against both EBOV and MARV cellular infections.
- To identify DAAC analogs with potent antiviral activity and low cellular toxicity for potential in vivo application.
Main Methods:
- Synthesis of three novel diazachrysene (DAAC) analogs with slight substituent modifications.
- Assessment of antiviral activity against EBOV and MARV in cellular infection models.
- Evaluation of inhibitor-mediated cellular toxicity for each analog.
- Determination of IC(50) values to quantify inhibitory potency.
Main Results:
- One DAAC analog exhibited significant efficacy, with IC(50) values of 0.696 µM ± 0.13 µM against EBOV and 2.76 µM ± 0.21 µM against MARV.
- This lead compound demonstrated minimal to no associated cellular toxicity.
- Structure-activity and structure-toxicity relationships were established for the tested DAAC analogs.
Conclusions:
- The study provides a framework for developing effective and safe DAAC-based filovirus inhibitors.
- The identified lead compound represents a promising candidate for further development as an antiviral therapeutic against EBOV and MARV.
- Optimized DAAC analogs hold potential for in vivo treatment of filovirus infections.
